# BioticsAI CEO on FDA Approval, Funding, and Healthcare's Regulatory Gauntlet

Robhy Bustami, CEO of BioticsAI, laid out the practical realities of building AI products in healthcare during a TechCrunch conversation with Isabelle Johannessen. The discussion centered on how his company has managed FDA approval processes, secured funding, and maintained team morale while navigating the industry's notoriously complex regulatory environment.

Healthcare AI startups face a fundamentally different path than consumer tech companies. FDA oversight requires extensive testing, documentation, and proof of safety before products reach patients. Bustami emphasized that this reality shapes every decision, from hiring to product roadmap prioritization. Teams must balance innovation speed with compliance demands that can stretch timelines by months or years.

The fundraising challenge compounds the regulatory burden. Investors want to see clear paths to revenue and market adoption. Yet healthcare's approval timeline creates a catch-22: companies burn capital during lengthy regulatory review periods before generating returns. Bustami's approach involves securing sufficient runway to weather FDA processes while demonstrating enough technical progress to keep investors confident.

Team motivation under these constraints requires deliberate leadership. Building in healthcare means celebrating milestones that wouldn't impress silicon valley. A successful FDA submission generates different momentum than a consumer app launch. Bustami noted that teams succeed when leadership clearly articulates the long-term vision and connects daily work to meaningful patient impact.

BioticsAI's strategy reflects a growing shift in healthcare AI. Rather than chasing hype, companies increasingly accept regulatory reality as a strategic moat. FDA approval creates legitimate barriers to entry that protect market position. Bustami's willingness to discuss these operational challenges signals confidence in his company's ability to execute through the regulatory process.

The conversation underscores a broader truth: healthcare AI requires different organizational DNA than consumer startups